Avelumab
- Generic Name
- Avelumab
- Brand Names
- Bavencio
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1537032-82-8
- Unique Ingredient Identifier
- KXG2PJ551I
- Background
Avelumab is a human IgG1 lambda monoclonal antibody that binds programmed cell death ligand-1 (PD-L1) to block its interaction with its receptors found on T cells and antigen-presenting cells. Avelumab was first approved by the FDA on March 23, 2017. On September 18 and December 18 of the same year, it was also granted approval by EMA and Health Canada, res...
- Indication
Avelumab is indicated for the treatment of adults with metastatic Merkel cell carcinoma (MCC). In the US, it is also used in patients 12 years and older.
...
- Associated Conditions
- Advanced Renal Cell Carcinoma, Metastatic Urothelial Cancer, Locally advanced Urothelial Carcinoma, Metastatic Merkel Cell Carcinoma (MCC)
- Associated Therapies
- First Line Chemotherapy, Maintenance therapy
Safety and Efficacy of Avelumab in Small Intestinal Adenocarcinoma
- First Posted Date
- 2016-12-21
- Last Posted Date
- 2022-04-14
- Lead Sponsor
- Vanderbilt-Ingram Cancer Center
- Target Recruit Count
- 8
- Registration Number
- NCT03000179
- Locations
- 🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
Randomized Trial of Avelumab-cetuximab-radiotherapy Versus SOCs in LA SCCHN (REACH)
- Conditions
- Interventions
- First Posted Date
- 2016-12-21
- Last Posted Date
- 2024-07-10
- Lead Sponsor
- Groupe Oncologie Radiotherapie Tete et Cou
- Target Recruit Count
- 707
- Registration Number
- NCT02999087
- Locations
- 🇫🇷
Centre Hospitalier Bretagne Sud, Lorient, France
A Phase Ib Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) of Avelumab in Combination With M9241(NHS-IL12) (JAVELIN IL-12)
- Conditions
- Interventions
- First Posted Date
- 2016-12-16
- Last Posted Date
- 2020-12-17
- Target Recruit Count
- 52
- Registration Number
- NCT02994953
- Locations
- 🇺🇸
St Joseph Heritage Healthcare, Santa Rosa, California, United States
🇺🇸Metairie Oncologists, LLC, Metairie, Louisiana, United States
🇮🇹IOV - Istituto Oncologico Veneto IRCCS, Padova, Italy
Avelumab and Azacitidine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia
- First Posted Date
- 2016-11-02
- Last Posted Date
- 2020-10-22
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 19
- Registration Number
- NCT02953561
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Study To Compare Avelumab In Combination With Standard of Care Chemoradiotherapy (SoC CRT) Versus SoC CRT for Definitive Treatment In Patients With Locally Advanced Squamous Cell Carcinoma Of The Head And Neck (JAVELIN HEAD AND NECK 100)
- Conditions
- Interventions
- First Posted Date
- 2016-11-02
- Last Posted Date
- 2021-09-22
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 697
- Registration Number
- NCT02952586
- Locations
- 🇺🇸
CBCC Global Research, Inc. at Comprehensive Blood and Cancer Center, Bakersfield, California, United States
🇺🇸Compassionate Care Research Group, Inc. at Compassionate Cancer Care Medical Group, Inc., Riverside, California, United States
🇺🇸University of Maryland, Greenebaum Comprehensive Cancer Center, Baltimore, Maryland, United States
Bioimmunoradiotherapy (Cetuximab/RT/Avelumab)
- Conditions
- Interventions
- First Posted Date
- 2016-10-19
- Last Posted Date
- 2019-12-11
- Lead Sponsor
- The Netherlands Cancer Institute
- Target Recruit Count
- 10
- Registration Number
- NCT02938273
- Locations
- 🇳🇱
Antoni van Leeuwenhoek, Amsterdam, Netherlands
Study of Avelumab With or Without Entinostat in Participants With Advanced Epithelial Ovarian Cancer
- Conditions
- Interventions
- First Posted Date
- 2016-09-27
- Last Posted Date
- 2024-01-10
- Lead Sponsor
- Syndax Pharmaceuticals
- Target Recruit Count
- 140
- Registration Number
- NCT02915523
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center and Research, Tampa, Florida, United States
🇺🇸HCA Midwest Health (SCRI Affiliate), Kansas City, Missouri, United States
🇺🇸University of Chicago, Chicago, Illinois, United States
Avelumab in Patients With MSS, MSI-H and POLE-mutated Recurrent or Persistent Endometrial Cancer and of Avelumab/Talazoparib and Avelumab/Axitinib in Patients With MSS Recurrent or Persistent Endometrial Cancer
- Conditions
- Interventions
- First Posted Date
- 2016-09-23
- Last Posted Date
- 2024-07-05
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 106
- Registration Number
- NCT02912572
- Locations
- 🇺🇸
University of Chicago, Chicago, Illinois, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
Avelumab for Recurrent/Metastatic Nasopharyngeal Cancer
- First Posted Date
- 2016-08-23
- Last Posted Date
- 2024-08-28
- Lead Sponsor
- Assuntina Sacco, M.D.
- Target Recruit Count
- 6
- Registration Number
- NCT02875613
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸UC San Diego Moores Cancer Center, La Jolla, California, United States
Avelumab for People With Recurrent Respiratory Papillomatosis
- Conditions
- Interventions
- First Posted Date
- 2016-08-09
- Last Posted Date
- 2021-11-02
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 13
- Registration Number
- NCT02859454
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.